Scholarlink

<p>Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with <i>HER2</i> mutations has not been widely investigated. SGNTUC-019 is an open-label, phase 2 basket study evaluating tucatinib, a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab in patients with <i>HER2</i>-altered solid tumors. The study included a cohort of 31 heavily pretreated female patients with <i>HER2</i>-mutated metastatic breast cancer who were also HER2 negative per local testing. Hormone receptor (HR)-positive patients also received fulvestrant. The overall response rate (primary endpoint) was 41.9% (90% confidence interval (CI): 26.9–58.2). Secondary endpoints of duration of response and progression-free survival were 12.6 months (90% CI: 4.7 to not estimable) and 9.5 months (90% CI: 5.4–13.8), respectively. No new safety signals were detected. Responses were observed across various <i>HER2</i> mutations, including mutations in the tyrosine kinase and extracellular domains. The chemotherapy-free regimen of tucatinib and trastuzumab showed clinically meaningful antitumor activity with durable responses and favorable tolerability in heavily pretreated patients with <i>HER2</i> mutations. These data support further investigation of HER2-targeted therapies in this patient population. ClinicalTrials.gov registration: <a href="https://clinicaltrials.gov/study/NCT04579380?term=NCT04579380&amp;rank=1">NCT04579380</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月17日

查看全文
  • Alicia F. C. Okines,
  • Giuseppe Curigliano,
  • Nobumasa Mizuno,
  • Do-Youn Oh,
  • Andree Rorive,
  • Hatem Soliman,
  • Shunji Takahashi,
  • Tanios Bekaii-Saab,
  • Mark E. Burkard,
  • Ki Y. Chung,
  • Philip R. Debruyne,
  • Jenny R. Fox,
  • Valentina Gambardella,
  • Marta Gil-Martin,
  • Erika P. Hamilton,
  • Bradley J. Monk,
  • Yoshiaki Nakamura,
  • Danny Nguyen,
  • David M. O’Malley,
  • Alexander B. Olawaiye,
  • Bhavana Pothuri,
  • Martin Reck,
  • Kazuki Sudo,
  • Yu Sunakawa,
  • Cedric Van Marcke,
  • Evan Y. Yu,
  • Jorge Ramos,
  • Sherry Tan,
  • Mark Bieda,
  • Thomas E. Stinchcombe,
  • Paula R. Pohlmann

摘要

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated. SGNTUC-019 is an open-label, phase 2 basket study evaluating tucatinib, a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab in patients with HER2-altered solid tumors. The study included a cohort of 31 heavily pretreated female patients with HER2-mutated metastatic breast cancer who were also HER2 negative per local testing. Hormone receptor (HR)-positive patients also received fulvestrant. The overall response rate (primary endpoint) was 41.9% (90% confidence interval (CI): 26.9–58.2). Secondary endpoints of duration of response and progression-free survival were 12.6 months (90% CI: 4.7 to not estimable) and 9.5 months (90% CI: 5.4–13.8), respectively. No new safety signals were detected. Responses were observed across various HER2 mutations, including mutations in the tyrosine kinase and extracellular domains. The chemotherapy-free regimen of tucatinib and trastuzumab showed clinically meaningful antitumor activity with durable responses and favorable tolerability in heavily pretreated patients with HER2 mutations. These data support further investigation of HER2-targeted therapies in this patient population. ClinicalTrials.gov registration: NCT04579380.